(BUSINESS WIRE)-- Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its second Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of potentially reduced-risk alternatives to cigarettes. The full issue is available here: https://www.pmiscience.com/news/smoke-free-products-scientific-update.
This issue of the Scientific Update focuses on novel approaches to e-vapor products. Technology and innovation can improve user experience and continuously enhance a product’s potential to present less risk of harm than smoking. The focus of the issue details the product design and manufacturing behind MESH, the new generation of e-vapor technology PMI is currently test marketing in Birmingham (UK). MESH is one of the four smoke-free product types developed by PMI, along with IQOS.
Prof. Manuel Peitsch, PMI’s Chief Scientific Officer, explains: “PMI is working to progressively transition its existing cigarette business to smoke-free products. By offering a diverse portfolio of innovative and scientifically substantiated alternatives, we believe we can accelerate the switching of an even greater number of adult smokers who would otherwise continue to smoke and have a positive impact on public health.”
Michele Cattoni, PMI’s VP Technology and Operations, further elaborates on the Company’s efforts: “Technological innovation is at the heart of PMI’s efforts to create a smoke-free future. We have developed an e-vapor product which, like our other smoke-free technologies, incorporates the highest manufacturing and design standards to ensure the consistency and quality of the generated vapor.”
Beyond the development behind PMI’s MESH proprietary technology, the Update provides an overview of its assessment to date. The issue also covers the latest studies, key peer-reviewed publications and presentations at scientific conferences. It is an important complement to PMI’s ongoing efforts to share its latest science, which include a dedicated website (www.pmiscience.com).
PMI’s extensive research and assessment program is inspired by the well-recognized practices of the pharmaceutical industry and in line with guidance of the U.S. FDA for Modified-Risk Tobacco Products (MRTPs). The Company today employs over 400 world-class scientists, engineers and experts who conduct rigorous research, including laboratory and clinical studies, as well as ground-breaking systems toxicology. The assessment program also includes studies on actual product use and correct understanding of product communications, as well as post-market research.
About Philip Morris International Inc. (“PMI”)
PMI is the world’s leading international tobacco company, with six of the world's top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of reduced-risk products (“RRPs”). RRPs is the term PMI uses to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see www.pmi.com and www.pmiscience.com.
Philip Morris International media office
T: +41 (0)58 242 4500